JP7168590B2 - ネクチン４結合性タンパク質及びその使用方法 - Google Patents

ネクチン４結合性タンパク質及びその使用方法 Download PDF

Info

Publication number
JP7168590B2
JP7168590B2 JP2019566609A JP2019566609A JP7168590B2 JP 7168590 B2 JP7168590 B2 JP 7168590B2 JP 2019566609 A JP2019566609 A JP 2019566609A JP 2019566609 A JP2019566609 A JP 2019566609A JP 7168590 B2 JP7168590 B2 JP 7168590B2
Authority
JP
Japan
Prior art keywords
seq
antibody
nectin
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522261A (ja
JP2020522261A5 (OSRAM
Inventor
ジェイン メイリック モリソン、カレン
ドネート、フェルナンド
ヤン、ペン
Original Assignee
アジェンシス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス インコーポレーテッド filed Critical アジェンシス インコーポレーテッド
Publication of JP2020522261A publication Critical patent/JP2020522261A/ja
Publication of JP2020522261A5 publication Critical patent/JP2020522261A5/ja
Application granted granted Critical
Publication of JP7168590B2 publication Critical patent/JP7168590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2019566609A 2017-06-05 2018-06-04 ネクチン４結合性タンパク質及びその使用方法 Active JP7168590B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515454P 2017-06-05 2017-06-05
US62/515,454 2017-06-05
PCT/US2018/035840 WO2018226578A1 (en) 2017-06-05 2018-06-04 Nectin-4-binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2020522261A JP2020522261A (ja) 2020-07-30
JP2020522261A5 JP2020522261A5 (OSRAM) 2021-07-26
JP7168590B2 true JP7168590B2 (ja) 2022-11-09

Family

ID=64566092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566609A Active JP7168590B2 (ja) 2017-06-05 2018-06-04 ネクチン４結合性タンパク質及びその使用方法

Country Status (10)

Country Link
US (1) US11292837B2 (OSRAM)
EP (1) EP3635013A4 (OSRAM)
JP (1) JP7168590B2 (OSRAM)
KR (1) KR102723905B1 (OSRAM)
CN (2) CN111675761B (OSRAM)
BR (1) BR112019025513A2 (OSRAM)
CA (1) CA3065514A1 (OSRAM)
MX (1) MX2019014318A (OSRAM)
TW (1) TWI870338B (OSRAM)
WO (1) WO2018226578A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
EP3890778A4 (en) 2018-12-03 2022-08-03 Agensys, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
CN110172455B (zh) * 2019-05-31 2020-03-17 江南大学 一种脂肪酶突变体及其在去污方面的应用
AU2020364959A1 (en) 2019-10-07 2022-04-07 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for Nectin-4 and uses thereof
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
US20230235054A1 (en) * 2020-06-18 2023-07-27 Bioatla, Inc. Conditionally active anti-nectin-4 antibodies
EP4168039A4 (en) * 2020-06-19 2024-12-04 Agensys, Inc. MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC)
US20230331867A1 (en) * 2020-09-04 2023-10-19 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
BR112022026611A2 (pt) * 2020-09-16 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticorpo ou fragmento de ligação ao antígeno do mesmo, conjugado de anticorpo, composição, receptor de antígeno quimérico, célula efetora imune, molécula de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para detectar a presença ou determinar o nível de expressão de nectina-4 em uma amostra
IL302818A (en) * 2020-11-25 2023-07-01 Innate Pharma Treatment of cancer
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
BR112023022098A2 (pt) * 2021-04-26 2023-12-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos
US12258402B2 (en) 2022-01-12 2025-03-25 Navi Bio-Therapeutics, Inc. Antibody specific to nectin cell adhesion molecule 4 and uses thereof
EP4496593A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
EP4310101A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibodies and antibody-drug conjugates
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
WO2024251260A1 (zh) * 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543498A (ja) 2010-09-29 2013-12-05 アジェンシス，インコーポレイテッド １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
WO2017042210A1 (en) 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747236A1 (en) 2004-05-12 2007-01-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4(n4) as a marker for cancer prognosis
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
JP2012511305A (ja) 2008-12-12 2012-05-24 オンコセラピー・サイエンス株式会社 癌の治療および診断の標的遺伝子としてのネクチン−４
WO2016203053A2 (en) 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543498A (ja) 2010-09-29 2013-12-05 アジェンシス，インコーポレイテッド １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
WO2017042210A1 (en) 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Res，2016年，76(10)，p. 3003-3013

Also Published As

Publication number Publication date
TW201902922A (zh) 2019-01-16
CA3065514A1 (en) 2018-12-13
EP3635013A4 (en) 2021-02-24
CN111675761B (zh) 2023-10-20
MX2019014318A (es) 2020-08-13
US11292837B2 (en) 2022-04-05
CN111675761A (zh) 2020-09-18
RU2019144030A3 (OSRAM) 2021-12-28
WO2018226578A8 (en) 2019-05-31
WO2018226578A1 (en) 2018-12-13
TWI870338B (zh) 2025-01-21
BR112019025513A2 (pt) 2020-06-23
RU2019144030A (ru) 2021-07-09
JP2020522261A (ja) 2020-07-30
US20200231670A1 (en) 2020-07-23
KR20200024788A (ko) 2020-03-09
CN111051345A (zh) 2020-04-21
KR102723905B1 (ko) 2024-10-31
EP3635013A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
JP7168590B2 (ja) ネクチン４結合性タンパク質及びその使用方法
US12084499B2 (en) SIRP-α binding proteins and methods of use thereof
EP3738981A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
EP3954999B1 (en) Compositions and methods for detecting and treating ovarian cancer
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
US11591390B2 (en) SIRP-α binding proteins and methods of use thereof
US20210380675A1 (en) Il-36 antibodies and uses thereof
WO2023009891A2 (en) Materials and methods of making or using il-23r binding proteins
RU2805252C2 (ru) Белки, связывающие нектин-4, и способы их применения
HK40037283A (en) Nectin-4 binding proteins and methods of use thereof
HK40037283B (zh) 柄蛋白-4结合蛋白及其使用方法
HK40026608A (en) Nectin-4 binding proteins and methods of use thereof
US20250189530A1 (en) Btn1a1 binding proteins and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221027

R150 Certificate of patent or registration of utility model

Ref document number: 7168590

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250